header logo image


Page 26«..1020..25262728..40..»

Archive for the ‘Death by Stem Cells’ Category

Company Spotlight: Cellect Biotechnology – RTT News

Friday, March 31st, 2017

Shares of Cellect Biotechnology Ltd. (APOP) are up more than 44% over the last 5 trading days.

With its shares currently traded on both the NASDAQ and Tel Aviv Stock Exchange, Cellect is the company behind ApoGraft, a breakthrough technology for the isolation of stem cells from any given tissue.

Cellect's ApoGraft technology is aiming to turn stem cell transplants into a simple, safe and cost effective process, reducing the associated severe side effects, such as rejection and many other risks, such as Graft versus Host Disease.

Graft versus Host Disease, a condition in which the transplanted immune cells attack the recipient's cells, is a common complication associated with *allogeneic stem cell transplantation. (*Allogeneic stem cell transplantation involves transferring the stem cells to the recipient from a genetically matched relative or other donor).

The positive results from a clinical trial of ApoGraft that involved 104 healthy donors of blood stem cells reported in February of this year demonstrated that Cellect's ApoGraft is a safe, robust and reproducible process for clinical use.

According to the company, the use of the ApoGraft to process human stem cells for bone marrow transplantation resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.

The first blood cancer patient was treated in a phase I/II trial of ApoGraft in February of this year, and on March 27th, the company announced that the first stem cell transplant procedure has been successfully performed.

With the first stem cell transplant procedure being successful, Cellect has received the go-ahead from the independent Data and Safety Monitoring Board for enrolling additional 2 cancer patients for ApoGraft transplantation treatments.

The study is designed to enroll 12 patients.

Key Financials:

- Net loss for the fourth quarter ended December 31, 2016 was $0.75 million or $0.007 per share compared to a net loss of $0.96 million or $0.012 per share in Q4, 2015.

- Cash totaled $8.0 million at December 31, 2016 compared to $3.1 million on December 31, 2015.

- The number of shares outstanding is 107.58 million (Data sourced from Yahoo Finance).

In order to maximize the value of the Company for all stakeholders, Cellect plans to delist from the Tel Aviv Stock Exchange (TASE) in accordance with section 350 to the Israeli Company Law.

Shares of Cellect Biotechnology touched an all-time intra-day high of $13.50 on Mar.27, 2017 on the NASDAQ. The stock closed yesterday's trading at $8.98, up 2.75%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

View original post here:
Company Spotlight: Cellect Biotechnology - RTT News

Read More...

Should a head transplant be allowed to happen? – Crux Now – Crux: Covering all things Catholic

Friday, March 31st, 2017

An Italian neurosurgeon is saying he plans on transplanting a head onto a donor body, not in some distant future, but by the end of 2017.

When Dr. Sergio Canavero first announced his plans a couple of years ago, most people thought he was either crazy, or it was a publicity stunt. Now Canavero says he will put the head of 30-year-old Russian Valery Spiridonov on a donor body in December. Spiridonov suffers from Werdnig-Hoffman disease, which is a form of spinal muscular atrophy.

The surgeon said the procedure would take humanity closer to extending life indefinitely.

Although Canavero insists everything is ready to go, a lot of the details remain murky, and it might still be more fantasy than reality.

Dr. David Albert Jones, the director of the Oxford-based Anscombe Bioethics Centre, says the risks associated with such an attempt are not justifiable.

The center is a Catholic academic institute that studies the moral issues surrounding medicine.

The current scientific and medical consensus is that this experiment has very little chance of success, Jones told Crux, adding the most likely outcome is either death during the operation or survival in a paralyzed state for a few hours or days.

Similar experiments have been done with small animals, to little success. No animal has ever come out of the procedure without being paralyzed, and they all have died soon after.

Jones said the studies are not even advanced enough to attempt the procedure on primates such as monkeys or chimpanzees, let alone a human subject.

There is nothing to suggest that the current proposal for a head transplant is realistic, Jones said, adding even if it were, it would not put mankind on a path to immortality.

People who have received donor organs live longer than they would have done, but they do not live longer, on average, than the average life expectancy of the general population, Jones said.

We will all die.

Jones did warn that if immortality became the goal of a society, this could be a real concern because the quest for unachievable goals can detract from the achievable goals of society, the realistic goals of healthcare, education and social solidarity.

Jones responded to some questions from Crux by email, and told us the scientific and ethical concerns about the proposed procedure.

Crux: Is this even possible with todays technology?

Jones: The idea of a head transplant (or a neck down body-transplant) has been attempted in animals but most animals have either died or have been completely paralyzed and none have lived more than a few days. Given the very poor outcome with mice at the present time it is very difficult to justify attempting this with primates, let alone with humans.

A key challenge is reconnecting the spinal cord. Only if we could finally overcome this problem in patients suffering from spinal cord injury (for example, by the use of gene therapy, stem cells and/or growth factors) would it be realistic to deliberately severe the spinal cord and reconnect the head to a different body.

Thought must also be given to the consequences if the body were to reject the new head. Could the head be kept alive apart from the body, and what kind of existence would this be?

Is such a transplant ethically permitted?

The current scientific and medical consensus is that this experiment has very little chance of success. The most likely outcome is either death during the operation or survival in a paralyzed state for a few hours or days.

The risks are such that it is not justifiable even with consent, but there is an added concern in that it seems likely that the patient has been given misinformation about the realistic prospects for success, and in these circumstances it seems doubtful that consent is properly informed.

It should also be noticed that the operation would not only take great financial and human resources but would also require a donor whose heart, lungs, liver, and/or kidneys could have given real benefits to several patients on the organ transplant waiting list. The opportunity costs would, at the very least, involve extending the suffering of these patients and could involve the death of a patient who might otherwise have been saved.

Many are saying that if such a surgery is successful, it puts humanity on the path to immortality. Should such a goal concern us?

There is nothing to suggest that the current proposal for a head transplant is realistic. If some time in the future the technical problems were overcome, it would not be the path to immortality any more than current, very successful, transplant medicine puts people on a path to immortality. People who have received donor organs live longer than they would have done, but they do not live longer, on average, than the average life expectancy of the general population. We will all die.

How can the Church do more to help people assess the morality of new biotechnologies and medical (or pseudo-medical) procedures?

The goal of immortality is unachievable. There is no need to be concerned therefore about the achievement of this goal. On the other hand if (virtual) immortality became the goal of a society, this could be a real concern because the quest for unachievable goals can detract from the achievable goals of society, the realistic goals of healthcare, education and social solidarity.

The virtue of temperateness is needed if society is to avoid such vain and destructive desires. The Church could do more to promote the virtues of temperateness and humility, which are necessary not only in relation to this issue but in the wider context of the care of creation.

How should the governments involved handle such things, both on a national and international level? I mean, it seems odd that this doctor is even being allowed to attempt this procedure, given the objections from many that the technology has not even been tested properly.

Governments should ensure that experimental surgery is subject to the same level of ethical scrutiny as the clinical trials of drugs or of medical devices. Unfortunately surgery is sometimes given a degree of latitude that leaves patients vulnerable to exploitation. Experimental procedures should not be permitted by a hospital unless and until it has been subject to scientific peer review and has satisfied a clinical ethics committee. It is difficult to see how the current proposal could fulfill such criteria.

Read the original here:
Should a head transplant be allowed to happen? - Crux Now - Crux: Covering all things Catholic

Read More...

Helping the retina regenerate – Science Daily

Friday, March 31st, 2017
Helping the retina regenerate
Science Daily
Amphibians do this naturally in response to RGC death from injury. Similarly, adult zebrafish regenerate RGCs by reprogramming cells in the retina called Mller glia. As outlined in the report, the workshop explored additional cell types for potential ...

Read more from the original source:
Helping the retina regenerate - Science Daily

Read More...

Drastic cuts to NIH budget could translate to less innovation and fewer patents, study argues – Los Angeles Times

Thursday, March 30th, 2017

From research on stem cells and DNA sequencing to experiments with fruit flies and surveys of human behavior, projects funded by the National Institutes of Health aim to make Americans healthier. A new analysis finds that NIH-funded research also fuels the kinds of innovations that drive the U.S. economy.

Between 1990 and 2012, close to 1 in 10 projects made possible by an NIH grant resulted in a patent, usually for a university or a hospital.

The indirect effects were far greater: Close to 1 in 3 NIH research grants generated work that was cited in applications for commercial patents.

Over roughly two decades, 81,462 patents filed by companies and individuals cited at least one NIH-sponsored research project in their applications. Some 1,351 of those patents were for drugs that would go on to be approved by the Food and Drug Administration.

The study, published Thursday in the journal Science, undergirds a point repeated frequently since the Trump administration unveiled a budget plan that proposed cutting the NIH budget by 20% in 2018: that research funded by taxpayer dollars not only improves lives and forestalls death, it creates jobs which the president has long asserted is his highest priority.

It is an argument often made in support of such scientific undertakings as space exploration, and sometimes for defense spending. But when it comes to biomedical research, public spending is frequently dismissed as a way to sustain university professors or seek esoteric answers to the mysteries of life.

It shouldnt be, said Pierre Azoulay, a professor of technological innovation at MIT and coauthor of the new analysis.

NIH public funding expenditures have large effects on the patenting output of the private sector, Azoulay said. These results should give a lot of pause to those who think these cuts are going to have no effect.

Ashley J. Stevens, a biotechnology researcher who is president of Focus IP Group in Winchester, Mass., said the new study clearly ... supports the premise that increased investment in the NIH leads directly to improved public health.

It also makes President Trumps proposal to cut the NIH budget by $1.6 billion this year and $6 billion next year to fund a border wall and increased military spending incompatible with his America first objectives, added Stevens, who was not involved in the study.

More than 80% of the NIH budget is parceled out to researchers across the country and around the world. Each year, NIHs 21 institutes award close to 50,000 competitive grants to investigators at more than 2,500 universities, independent labs and private companies. The University of California, for instance, received nearly $1.9 billion in total NIH funding last year.

Led by Harvard Business School entrepreneurship professor Danielle Li, the new research scoured 1,310,700 patent applications submitted between 1980 and 2012 in the life sciences, a category that includes drugs, medical devices and related technologies. In the footnotes, citations and supporting data, the study authors looked for references to any of the 365,380 grants the NIH funded between 1980 and 2007, as well as to research articles generated by those grants.

To capture the unappreciated indirect spillovers of knowledge that result from NIH-funded work, the authors focused especially on 232,276 private-sector patents in the life sciences.

Li, Azoulay and Bhaven Sampat, a health policy professor at Columbia University, found 17,093 patents that were assigned to universities and public-sector institutions. These patents are certainly valuable they can spur further research, support professors and graduate students and boost endowments.

But private-sector patents may reverberate more widely through the economy, generating capital, manufacturing jobs and profits. And their intellectual debt to publicly funded research is rarely counted or acknowledged outside the fine print of these patent applications.

In all, 112,408 NIH-funded research grants 31% of the total disbursed between 1990 and 2007 produced research that was cited by 81,462 private-sector patents, the team found.

If you thought this was just ivory tower stuff that has no relevance, I think we contradict that, Azoulay said.

The findings demonstrate that the broad economic effects of NIH budget cuts would not necessarily be felt immediately, since it could take years for a research paper written by NIH-funded investigators to find its way into a patent application.

These effects are going to be delayed, Azoulay said. The slowdown resulting from a cut in the NIH budget now is for President Ivanka Trump or President Chelsea Clinton to worry about.

But the study also makes clear that publicly funded research lays the groundwork for important innovations and discoveries that companies and individuals seek to patent.

Biomedical research is perhaps the most complex type of research there is, Azoulay added: These are fundamentally harder problems. There are a lot of blind alleys, experimentation that leads to nothing.

Intriguingly, the new research found that there was little difference in the economic impact of grants for basic science and applied science. Both types of grants were equally likely to be cited in patent applications if they explored fundamental dynamics of biology (such as cellular processes) or if they studied specific disease states in humans.

That distinction is important, because researchers and scientific leaders have quarreled for years over how NIHs limited budgets should be apportioned.

Scientists who study very basic biological processes, or who work with simple organisms like yeast, earthworms or fruit flies, often argue that their contributions are most valuable because they shed light on how all life including human life works.

Scientists whose research is more applied, including clinical trials and epidemiological studies, believe their work contributes more directly to improving human health.

The new study suggests that both categories contribute to commercial innovation.

Stevens called this finding remarkable.

Azoulay acknowledged that neither the progress of life sciences research nor its contribution to the economy is neat or easy to quantify.

More:
Drastic cuts to NIH budget could translate to less innovation and fewer patents, study argues - Los Angeles Times

Read More...

The life-saving treatment that’s being thrown in the trash – Ars Technica

Thursday, March 30th, 2017

Enlarge / A little needlework and blood has never looked better.

MaricorMaricar @ Handsome Frank

A few hours before beginning chemotherapy, a man named Chris faces his cellphone camera with a mischievous smile and describes a perfectly absurd milestone at 1:37pm on a Wednesday. There is no more beautiful moment in a mans life he says with puckish glee. Because how can you not laugh when youve been invited to bank your sperm in advance of being Godzilla-ed with chemotherapy and radiation, all just four days after being diagnosed with acute myeloid leukemia at the age of 43 and given a 5 to 15 percent chance of survival?

Oh, and the fertility clinic forgot to send someone over with a specimen kit, and theyre closing in little more than 20 minutes, so you have to fire up your iPad for some quick visual stimulation to help you fill a sterile tube. Just try to ignore the legal consent paperwork all around you and the catheter thats been surgically inserted into your jugular vein.

And because there are no couriers available, your sisterwho has been running half-marathons to get in shapegamely volunteers to tuck the freshly filled tube in her sports bra to keep it at body temperature before dashing the mile to the clinic. You imagine her arriving as the window is closing, lurching towards the counter and shouting Nooooo! in the slow-mo way they do in action movies. She hands over her precious cargo in the nick of time and triumphantly exclaims, This is my brothers!

Nothing is normal about leukemia or its aftermath, and Chris Lihosit has chosen to cope by learning everything he can about the disease and poking fun at its many indignities and absurdities. While some people with cancer are reluctant to share because they see it as a sign of weakness, he knows that humour and openness have a way of breaking the ice and maintaining visibility.

On the last day of 2015, Chris received one of the estimated 40,000 umbilical cord blood transplants performed around the world to date. Cord blood contains what are known as stem cells and progenitor cells, which can give rise to oxygen-carrying red blood cells, infection-fighting white blood cells, and clot-forming platelets.

Transplanted cord blood can be used to treat or cure more than 80 conditions, from leukemia to sickle-cell disease. Based on current research exploring autism, brain injury, cerebral palsy, type 1 diabetes, and cardiovascular disease, among others, the list of potential applications is likely to grow. Emerging strategies are even transforming cord blood left over after birth into a potent potion that might provide lifesaving treatments for victims of a nuclear disaster.

Stem and progenitor cells are also found in the spongy marrow within some bones and in the blood that circulates around our bodies. But cord blood, once dismissed as medical waste, is particularly rich in these cells. As researchers are discovering, it may carry other significant advantages, too.

While a cord blood transplant might save your life, though, going through the process and then starting anewyour survival down to an anonymous babyis far from easy.

The first cases of leukemia were documented some 200 years ago. The earliest known reports, by Scottish surgeon Peter Cullen in 1811 and French surgeon Alfred Velpeau in 1827, chronicled a baffling ailment marked by an enlarged spleen. Cullen described the mysterious transformation of his patients blood serum from a clear pale yellow to a milky liquid. Velpeau was just as astonished by what he likened to a thick gruel, leading him to conclude that his dead patients blood was full of pus.

As we now know, bone marrow produces cells called blasts," which take time to grow into infection-fighting white blood cells. But leukemia sends production into overdrive, filling the blood with blasts that dont develop as they should. This army of immature cells crowds out the useful ones, leaving the host highly vulnerable to internal bleeding or foreign invaders.

Although the risk factors for leukemia are only partly understood, scientists have linked it to genetic disorders such as Fanconi anaemia and Down syndrome, and to exposure to radiation or toxins like benzene. The out-of-control growth of abnormal white blood cells, though, has provided an opening for drug and radiation therapies that selectively cull the bodys fastest-growing cells. As a last resort, doctors may deliberately kill off all leukemia-riddled blood and bone marrow cells and attempt a full reset with someone elses blood-forming stem cells.

In early August 2015, Chris Lihosit fell ill with an exhausting, dehydrating, and pajama-soaking fever that mysteriously disappeared two days later. During a check-up, on his 43rd birthday, his doctor named summertime flu the most likely culprit.

Then the same thing happened again, and it settled into a disturbing pattern: midweek chills and an escalating fever that would break on Sunday. By Monday, Chris would feel fine, only to have the sequence repeat itself. He joked about it with colleagues at T-Mobile, where he works in software development, Well, I hope its not cancer!

On alternating weekends from May to October, Chris would volunteer as a backcountry ranger for the US Forest Servicea physically demanding role that involves patrolling Washingtons Cascade Mountain forests and hiking along high-altitude trails with a backpack that can weigh up to 32 kilograms. But now, even at sea level, he was getting winded just walking his two dogs around the block. What the hell was going on?

A medical appointment revealed a heart murmur and suspicions of endocarditis, an infection of the hearts inner lining. The scare triggered another series of tests that led Chris and his husband, Bill Sechter, to Emergency Room 4 at the University of Washington Medical Center.

A whiteboard checklist documented his Saturday morning: insertion of a large-bore IV as a potential conduit for antibiotics, a round of blood draws, and discussions with the ER doctor. Then the phone rang and the nurse answered, listened and responded to multiple questions in quick succession: Yes. Yes. Oh, OK. OK. Yeah. He excused himself from the room and soon returned in a full hazmat suit," as Chris describes it. Yellow.

And thats when we were like, Oh shit, its on. Something is seriously bad.

Chris learned that his level of infection-fighting neutrophil cells, normally churned out by the bone marrow, had fallen so low that his defences were in tatters. He was also severely anaemic, with roughly half the normal amount of red blood cells in his blood.

It wasnt endocarditis. And when one of his doctors performed a blood smear, she saw something on the microscope slide that shouldnt be there: blasts. These leukaemic cells, stuck in adolescence, were the harbingers of the coming horde that had so astonished 19th-century surgeons.

The doctor apologetically broke the news, and Chris and his sister dissolved into tears. In an emotional Facebook post later that day, he attached a picture of himself in a hospital gown and pink facemask and wrote: this avowed agnostic could actually go for your good juju / positive thoughts or even your (gasp) prayers.

More tests, including a bone marrow biopsy of his pelvic bone, painted an increasingly disturbing picture. He had acute myeloid leukemia, a fast-progressing cancer. The biopsy suggested that an astonishing 80 percent of his bone marrow cells were cancerous. Strike one.

Other results suggested that chemotherapy wouldnt be as effective on his form of leukemia. Strike two.

And genetic tests put him in the unfavourable risk category by revealing that his cancer cells carried only one copy of chromosome 21, a rare anomaly associated with dismal outcomes, according to recent studies. Strike three.

Chris needed to start chemotherapy immediately. But first, he had his sperm banked. Then, with family and a close friend at his side, he celebrated his impending treatment with prime rib and cheap champagne smuggled into his hospital room.

Over three days, he received multiple doses of the anticancer drugs cladribine, cytarabine, and mitoxantrone, the last a dark blue concoction often dubbed Blue Thunder." The drug turned his urine a shade he describes as Seahawks green in honour of Seattles football team. Other patients have had the whites of their eyes temporarily turn blue.

On the third night of his drug infusion, a sudden back pain grew into an intense pressure in his chest that felt like he was being stabbed. A heart attack? An emergency CAT scan instead revealed two newly formed blood clots: one in his right leg and another in his right lungnot uncommon consequences of chemotherapy.

Over the next six months, Chris would need transfusions of blood-clotting platelets whenever his level of them dipped too low, and daily injections of a blood-thinning drug whenever it rose too high. Thirteen days after being admitted into the hospital, he posted a more hopeful Facebook entry: And Im finally going home! Now the real adventure begins.

View original post here:
The life-saving treatment that's being thrown in the trash - Ars Technica

Read More...

‘The 100’ Recap: Jaha Searches for the Second Dawn – BuddyTV (blog)

Thursday, March 30th, 2017

On this episode of The 100, "God Complex," Abby and the others deal with a crushing blow, Clarke prepares to make the ultimate sacrifice, and Jaha finds new evidence that leads him and Kane in search of the Second Dawn.

Nobody on the island (with the exceptions of Emori and Murphy) feels good about experimenting on Baylis. But the killer "death" wave of radiation is due to hit in ten days. Luna's stem cells grafted successfully, and Baylis is generating Nightblood on his own, so it's now or never. Clark remains the most vocal supporter of turning the guy into a deep-fried Twinkie. Murphy reminds everyone that the black rain already killed 18 people in Arkadia, so if the Nightblood is going to help him survive the next storm, he's ready to find out.

Epic Fail

Things start out promising with Baylis showing no ill-effects, but the experiment eventually goes south with Baylis being scorched, screaming in pain and vomiting up blood. He dies in the chamber. This is a huge bummer since the Nightblood was the only plan, and they tortured and killed a man for no good reason.

From the Ashes

Back at Arkadia, the survivors of the black rain hold a memorial for the dead. Jasper remains footloose and fancy free, showing no concern about what lays ahead. He decides to ditch and go on a walkabout, and Bellamy, worried about his friend's ambivalence about possibly dying at any time, decides to tag along.

Niyah performs her own little ritual, stating "From the earth we will grow. From the ashes we will rise." Jaha overhears Niyah and asks where she heard that phrase. She tells him he'll have to ask a Flamekeeper. All she knows is that's whatGrounders sayto ready their dead for the fire.

Jaha goes to Kane. He's now convinced that the bunker Clarke, Bellamy and himself found was a decoy, meant for members of the Second Dawn who hadn't yet ascended to level 12. It was a way to prevent the real bunker from being overrun. Jaha believes there's a reason "From the ashes we will rise" became a Grounders' prayer. Just like a corporate logo became a sacred symbol.

Jaha's theory is enough of a reason for Kane to decide to reach out to Indra to try and find out Gaia's whereabouts. Jaha is eager to assemble a team, but Kane warns him Polis is a war zone, and they won't be welcome. Jaha plans to travel light, and this mission calls for thinkers, not warriors.

First Survival Then Humanity

At the lab, Jackson figures out what may have caused their experiment to fail. They can try again, but they need another test subject. Luna isn't down with going out to hunt for another Grounder, pointing out that even Baylis honored the dead by wearing the stones of his Rock Line ancestors. After putting the pieces together, Clarke realizes the man wasn't Baylis after all and asks Emori who they just killed. Emori yells to Murphy to destroy the machine and tries to flee but is held by Roan.

The others lock up Emori and Murphy, but Raven isn't okay with the prospect of putting Emori in the radiation chamber. Clarke doesn't know what else to do, and Roan says they don't have a choice. Raven believes there has to be another way to solve their problem that doesn't make them murderers, but the only thing Abby knows for sure is if they do nothing, everyone dies.

Abby orders Jackson to prep Luna for another extraction, but she refuses. She won't let her blood kill anymore innocent people. She's set to go out into the black rain so nobody can follow, but Roan won't allow her to leave. Luna questions if there's any line they won't cross in order to survive. Roan responds that survival requires sacrifice. If Emori dies saving the world, that's a good death.

Luna is wounded from the bone marrow biopsy, and Roan doesn't want to fight her, but she leaves him no choice. Luna isn't much of a match, and Roan renders her unconscious. Raven is mortified that Abby plans to strap Luna down and forcibly take her marrow and equates Clarke and the others with the scientists at Mt. Weather.

Roan gives Clarke a pep talk. She's filled with doubt about whether they're doing the right thing. Roan says that certainty is a luxury leaders can't afford. Clarke may not be a king, but she's a born leader, and she doesn't back down when things get hard. Roan is certain one day people will thank her for what she's doing on the island. Clarke doesn't think Murphy or Emori will, but Roan thinks they will if it works. Clarke worries what happens if it doesn't, but then it's kind of a moot point since they'll all be dead.

The time comes to put Emori in the chamber, and Murphy begs Clarke not to do it. When that doesn't change her mind, Murphy promises Clarke that if Emori dies, she's next. Abby can't bring herself to inject Emori with the Nightblood, leaving it up to Clarke to do her dirty work. But, instead, Clarke injects herself.

Abby refuses to let Clarke go in the chamber, telling her daughter she had a vision that Clarke would die, just like Raven's vision of the rocket. Abby destroys the chamber, smashing it so until it's useless.

It's the End of the World and Jasper Feels Fine

Bellamy and Jasper wander into the forest, and Bellamy grows tired of Jasper's jokes about the end of the world. Jasper tells Bellamy he's trying to help him. The clock has been ticking since they landed on Earth. They're all living on borrowed time. Bellamy wonders if that's what Jasper truly believes, why is he wasting it, but Jasper remains steadfast that he's not, it's Bellamy who is.

Bellamy keeps beating himself up about all the terrible things that he's done, and even if he thought he had good reasons, in the end, nobody gives a damn about Bellamy's reasons. No matter how much Bellamy punishes himself, it won't bring anyone back. Jasper says they can spend their last days wallowing, or they can do whatever they want.

Bellamy and Jasper return to Arkadia, and everybody's partying. Jasper's brought back some "magic beans" (hallucinogenic nuts) to amp up the festivities. Bellamy makes a half-hearted effort to be a buzz kill, but peer pressure wins out.

The 12th Seal

Kane, Jaha and Monty arrive in Polis and discover the black rain fell there too, leaving a number of casualties. They are also greeted by a small army ofTrikru led by Indra. Kane thanks her for meeting with him, but she punches him in the face. Indra's not interested in pleasantries, she just wants to know why Kane is in Polis. As the ally of her enemy, he and Skaikru are now her enemies as well.

Kane tries to explain that Skaikru is still trying to save everyone, but all Indra sees is that they made a truce with Azgeda, seemingly leaving Trikru to fend for themselves. Kane emphasizes that they must all work together, and he needs to see Gaia since she could be the key to saving them all.

Luckily, Gaia is in Polis, and Indra takes the men to see her. Monty spots a tattoo on her shoulder, and it's the same symbol on theseal that Jaha took from the bunker. According to Gaia and Indra, it's the holy symbol of their order. Gaia reveals the symbol adorns the crypt of the first Commander, Becca Pramheda.

The crypt is located in a temple controlled by the Azgeda. Indra is ready to fight to get in, but Kane says they have the royal seal/medallion (given to them by Roan) and don't have to, especially since Azgeda is Skaikru's ally. Indra thinks Kane is foolish to assume Azgeda will honor the medallion. The closer they get to Praimfaya, the less alliances mean.

They arrive at the temple, Kane shows themedallion and they are given permission to pass. But Indra guns down all of the guards anyway. If there is a bunker, she's determined Azgeda will never see the inside.

They head inside the temple, and Gaia shows them the symbol which is located beneath the alter. Jaha and Kane try to figure out how to open the crypt, and they don't have much time with more Azgeda returning to the temple. Monty figures out that "From the ashes we will rise" isn't just a motto, it's instructions. They drop theseal into fire, and it becomes the 12th seal. They open the crypt and find a staircase. At the bottom, there's another bunker.

Who will go into the bunker? Who will be left out? Is there still a chance Abby will find another solution? Let us know what you think in the comments section below.

(Image Courtesy of The CW)

Read more:
'The 100' Recap: Jaha Searches for the Second Dawn - BuddyTV (blog)

Read More...

Immune cell therapy on liver cancer using interferon beta produced with stem cells – Medical Xpress

Wednesday, March 29th, 2017

March 29, 2017 (A) Bio-imaging analysis to evaluate the therapeutic effect of iPS-ML producing IFN- on metastatic liver cancer. (B) Quantification of the image data shown in A. (C) Histological data indicating migration of iPS-ML (PKH26, red) into intrahepatic tumor tissues (GFP, green). Adapted from M. Sakisaka, M. Haruta, Y. Komohara, S. Umemoto, K. Matsumura, T. Ikeda, M. Takeya, Y. Inomata, Y. Nishimura, and S. Senju, "Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-," Journal of Hepato-Biliary-Pancreatic Sciences, vol. 24, pp. 109-119, Feb. 2017. DOI: 10.1002/jhbp.422

Causes of the most common form of liver cancer, hepatocellular carcinoma (HCC), include hepatitis B or C, cirrhosis, obesity, diabetes, a buildup of iron in the liver, or a family of toxins called aflatoxins produced by fungi on some types of food. Typical treatments for HCC include radiation, chemotherapy, cryo- or radiofrequency ablation, resection, and liver transplant. Unfortunately, the mortality rate is still quite high; the American Cancer Society estimates the five-year survival rate for localized liver cancer is 31 percent.

Hoping to improve primary liver cancer outcomes, including HCC and metastatic liver cancer, researchers from Japan began studying induced pluripotent stem (iPS) cell-derived immune cells that produce the protein interferon- (IFN-). IFN- has antiviral effects related to immune response, and exhibits two antitumor activities, the JAK-STAT signaling pathway and p53 protein expression. IFN- has been used for some forms of cancer, but problems like rapid inactivation, poor tissue penetration, and toxicity prevent widespread use. To overcome that hurdle, Kumamoto University researchers used iPS cell-derived proliferating myelomonocytic (iPS-ML) cells, which they developed in a previous research project. These cells were found to mimic the behavior of tumor-associated macrophages (TAMS), which inspired the researchers to develop them as a drug delivery system for IFN- and evaluate the therapeutic effect on liver cancer in a murine model in vivo.

The researchers selected two cancer cell lines that were sensitive to IFN- treatmentone that easily metastasized to the liver after injection into the spleen, and another that produced a viable model after being directly injected into the liver. After injection, mice that tested positive for cancer (~80 percent) were separated into test and control groups. iPS-ML/IFN- cells were injected two to three times a week for three weeks into the abdomens of the test group subjects.

Livers with tumors were found to have higher levels of IFN- than those without. This was likely due to iPS-ML/IFN- cells penetrating the fibrous connective tissue capsule surrounding the liver and migrating toward intrahepatic cancer sites. The iPS-ML/IFN- cells did not penetrate non-tumorous livers, but rather stayed on the surface of the organ. Furthermore, concentrations of IFN- from 24 to 72 hours after iPS-ML/IFN- injections were found to be high enough to inhibit proliferation or even cause the death of the tumor cells.

Due to differences between species, mouse cells are not adversely affected by human IFN-, meaning that side effects of this treatment are not visible in this model. Thus, the researchers are working on a new model with the mouse equivalent of human iPS-ML/IFN, and testing its therapeutic abilities.

"Our recent research into iPS-cell derived, IFN- expressing myeloid cells should be beneficial for many cancer patients," says research leader Dr. Satoru Senju. "If it is determined to be safe for human use, this technology has the potential to slow cancer progression and increase survival rates. At this point, however, we still have much work ahead."

This research may be found in the Journal of Hepato-Biliary-Pancreatic Sciences.

Explore further: Scientists stimulate immune system, stop cancer growth

More information: Masataka Sakisaka et al, Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-, Journal of Hepato-Biliary-Pancreatic Sciences (2017). DOI: 10.1002/jhbp.422

A chemical found in tumors may help stop tumor growth, according to a new study.

Scientists at EPFL have found a way to starve liver cancer cells by blocking a protein that is required for glutamine breakdownwhile leaving normal cells intact. The discovery opens new ways to treat liver cancer.

Most cases of liver cancer develop after long-term viral infection, chronic exposure to alcohol, or excessive accumulation of fat in the liver due to obesity. The liver reacts to those insults by trying to wall it off with ...

Liver cancer remains among the leading causes of cancer-related death worldwide.

Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated ...

Immunotherapydeveloping treatments by boosting natural immune system responsesholds much potential in the fight against serious diseases. Now, A*STAR researchers have determined how one group of immune cells called ...

Purdue researchers are developing technology that could lead to the early detection of cervical cancer with low-cost, easy-to-use, lateral flow test strips similar to home pregnancy tests.

One reason pancreatic cancer has a particularly low survival rate is the difficulty in getting drugs to the tumour, but new knowledge of how pancreatic cancer cells invade neighbouring cells could change that.

The chemical bisphenol A, or BPA, appears to aid the survival of inflammatory breast cancer cells, revealing a potential mechanism for how the disease grows, according to a study led by researchers in the Department of Surgery ...

Researchers at Mayo Clinic have identified an interaction among proteins that allows cancer cells to grow and metastasize. They say the discovery may play a role in developing a better understanding of how tumors grow in ...

The goal of cancer therapy is to destroy the tumor or stop it from growing and spreading to other parts of the body. Reaching toward this goal, a team of researchers from various institutions, including Baylor College of ...

In many parts of the world, including Southeast Asia and sub-Saharan Africa, exposure to a fungal product called aflatoxin is believed to cause up to 80 percent of liver cancer cases. This fungus is often found in corn, peanuts, ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

The rest is here:
Immune cell therapy on liver cancer using interferon beta produced with stem cells - Medical Xpress

Read More...

Stem-cell therapy: The medicine of the future – Ynetnews

Wednesday, March 29th, 2017

In one of the famous scenes of American animated sitcom Family Guy, which was aired on January 2008, the main character, Peter Griffin, is seen entering a stem cell research lab with half his body paralyzed, as a result of a stroke, and walking out completely healthy.

Growing a heart on a plate (PR photo)

Imagination plays an important role in dealing with stem cells. Theoretically, cells that, in a lab, can differentiate into any specialized cell present countless options of playing with the human bodyfrom treating any physical medical failure, through preparing a bank of human spare parts, to producing a new race of perfect human beings, completely flawless and immune. That is only in theory, however, at least at this stage. In practice, the possibilities inherent in stem cells are still imaginary, and using them for actual treatment is still very limited.

Torontos skyline is dotted with multi-story buildings, each with a series of elevators that fly visitors within second from the ground floor to the upper floors. The 35th floor of Eaton Centre, a shopping mall and office complex located near Dundas Squarewhich locals say is like Times Square, only a lot less impressiveoverlooks almost all parts of the Ontario provinces capital.

Using stem cells for the sake of humanity (Illustration photo: Shutterstock)

The most fascinating research has to do with cardiology. This is the field in which the ability to imagine a new era in the near future appears most palpable. Its difficult to overstate the complexity of the human heart, which is made up of different types of cells and tissues and is activated through a sequence of electrical pulses. Modern medicine has been unsuccessful so far in creating an industrial alternative for the heart, at least not one that allows a quality of life, while transplant surgery suffers from the risks of transplant rejection and a regular donor shortage. These limitations, in addition to the fact that heart diseases are very common and are one of the leading causes of death around the world, make cardiology a fertile ground for an industry of innovative medicine.

PR photo

One field in which this vision has already become a reality, at least partially, is lung therapy. Stem cell medicine holds a potential in terms of lungs suitable for transplantation, when it comes to improving of the chances that the new body wont reject the organ. The entire process, however, is complicated. Lung transplantation is only possible when the person who agreed to donate his organs in advance is declared brain dead, which makes it possible to harvest the organs before the entire body collapses, and these are pretty specific cases. In addition, in this group only 20 percent of the donated lungs are eventually transplantedas the procedure must be quick, and in most cases doctors dont have sufficient information about the lungs condition and the ability to prepare it for a transplantation which wont be rejected.

PR photo

In the stem-cell therapy labs in Toronto, the future is both present and absent. Most researchers refuse to fall into the press trap and talk about a vision for a better future in which every problem will be treated by injecting stem cells. And although the phrase growing a heart on a plate is occasionally heard, they make sure to clarify that such a situation is still far off. Nevertheless, no one will deny that stem-cell therapy is the medicine of the future.

The combination of medical and technological innovations may have brought humanity to the start of a new era, in which it will be possible to cure the body in an immensely more efficient way than in the past. But even these accomplishments highlight how little we know about the human body and how much more we need to learn and work in order to be able to unlock the full potential hiding deep within our cells.

(Translated and edited by Sandy Livak-Furmanski)

View post:
Stem-cell therapy: The medicine of the future - Ynetnews

Read More...

Better Buy: Bellicum Pharmaceuticals, Inc. vs. Kite Pharma – Motley Fool

Wednesday, March 29th, 2017

The next shoe is set to drop in the high-flying immuno-oncology space, with genetically modified cell therapies close to becoming a reality. As these therapies are forecast to quickly become one of the fastest-growing segments of the $100 billion oncology market in the next few years, investors may want to consider taking a position in this emerging field before the first therapy reaches the market.

Armed with this insight, let's consider if the small-capBellicum Pharmaceuticals (NASDAQ:BLCM) or the mid-capKite Pharma (NASDAQ:KITE) is the better adoptive-cell therapy stock to buy.

Image source: Getty Images.

Bellicum is a small-cap biotech developing a host of genetically modified cell-based therapies for blood disorders and various cancers. While cell-based immunotherapies are now a common feature of many pharma pipelines, Bellicum stands apart from the crowd because of itsproprietary "chemical induction of dimerization" (CID) technology that's designed to enhance the safety and efficacy profiles of these novel cancer-fighting cell therapies.

Specifically, the biotech's cellular therapies incorporate a molecular switching mechanism that can be triggered by a small molecule known asrimiducid to either induce programmed cell death (apoptosis) in the event of a safety issue, or cause the infused cells to proliferate to enhance potency.

Using its CID platform, Bellicum designed its lead T-cell therapy product candidate, BPX-501, to improve patient outcomes during a half-matched T-depleted, hematopoietic stem-cell transplantation (HSCT) -- a process that involves theintravenous infusion of stem cells as a way to restart the production of blood cells in patients with bone-marrow or immune-system disorders.

Although half-matched HSCT can be life-saving in many instances, this procedure does have serious life-threatening drawbacks, such as graft-versus-host-disease (GvHD) or an increased risk of infection from the eradication of T-cells before infusion. BPX-501's built-in safety switch, however, should solve this problem by lowering the risk of uncontrolled bouts of GvHD, while still allowing patients to benefit from a higher T-cell count.

The good news is that the therapy's early-stage results across a range of rare blood disorders are proving to be a game changer for many HSCT patients. As such,Bellicum is hoping to file for BPX-501's first regulatory approval in the EU by mid-2018 and nail down an acceptable regulatory pathway for the therapy in the U.S. by the middle of this year.

The downside, though, is thatthe biotech's cash runway probably isn't sufficient to see it all the way through to BPX-501's worldwide commercialization. Bellicum, after all, has around $150 million remaining in cash following its latest secondary offering, but it also has a quarterly burn rate of around $20 million that's bound to grow as its clinical activities expand into late-stage development.

After a quarter-century of development of adoptive T-cell therapies in general, Kite Pharma is now in prime position to bring the first chimeric antigen receptor T-cell (or CAR-T) therapy to market with its experimentalaggressive non-Hodgkin lymphoma (NHL) treatment called Axi-Cel (formerly KTE-C19). At the time of writing, Kite was expected to wrap up Axi-Cel's full regulatory filing with the FDA within just a matter of days (before the end of March), putting it well ahead of Novartis and Juno Therapeutics' rival CAR-T candidates.

The point is that Kite is set to be the first company to establish a foothold in a brand-new oncology market that should easily be worth hundreds of billions in sales over the next decade. Moreover, Axi-Cel's first indication isn't a token one. If approved as a later-line treatment for aggressive NHL, this novel cell therapy is expected to haul in between $181 million and $482 million in 2018, depending on its price and the scale of Kite's initial commercial launch.

Having said that, Kite is far from a slam-dunk buy. Like all other CAR-T therapies to date, Axi-Cel does have serious life-threatening side effects, including cytokine release syndrome and neurologic toxicity, and this therapy lacks a top-flight molecular safety switch. So while its overall risk-vs.-reward profile may warrant an approval, there's no telling how doctors will view the therapy's clear-cut trade-offs in the real world.

Kite must also overcome the inherent problems associated with manufacturing an adoptive T-cell therapy on a commercial scale. Put simply, you have to be able to harvest a patient's own T-cells, ship them to your production facility to genetically modify them, and then ship them back to the clinic where the patient is being treated. That's not an impossible feat to overcome, but it's also a far cry from simply brewing a batch of pills, or even manufacturing most other biological-based drugs.

On the bright side, Kite is in a fairly strong financial position, exiting the most recent quarter with over $414 million in cash and no debt. And that's before the company rolled out a $410 million public stock offering in the first quarter of 2017. So the company should have the resources to executeAxi-Cel's commercial launch if it gains an approval later this year, as well as continue advancing its other clinical candidates.

While Kite's possible first-mover advantage is certainly important, Bellicum appears to have the best-in-class technology with its CID platform. And that's absolutely key.

The underlying reason adoptive-cell therapies took so long to move from the bench to the market is their deadly side effects. Kite, for its part, has been able to reduce these life-threatening side effects to manageable levels in the clinic, but that's not a guarantee this line will hold once Axi-Cel is used more broadly.

Juno Therapeutics'lead clinical candidate, JCAR015, after all, was ultimately shelved after it apparently led to ahandful of deaths in a trial for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and that's been par for the course with these therapies.In other words, history is not on Kite's side when it comes to the current generation of CAR-T therapies.

So Bellicum's next-generation adoptive-cell therapy product candidates -- along with Juno and Kite's, for that matter -- that incorporate more robust safety features are probably the way to go if you're looking to invest in this emerging space. Point blank: This rush to market for a technology with known safety issues is a highly questionable strategy that has the potential to backfire in a big way.

In all, Bellicum comes out the winner in this match because of its patience and better long-term prospects from a safety standpoint.

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.

View original post here:
Better Buy: Bellicum Pharmaceuticals, Inc. vs. Kite Pharma - Motley Fool

Read More...

First patient cured of rare blood disorder with stem cell transplant – Guardian

Wednesday, March 29th, 2017

*New form of tissue engineering raises ethical questions Using a technique that avoids the use of high-dose chemotherapy and radiation in preparation for a stem cell transplant, physicians at the University of Illinois Hospital & Health Sciences System, United States, have documented the first cure of an adult patient with congenital dyserythropoietic anemia. CDA is a rare blood disorder in which the body does not produce enough red blood cells, causing progressive organ damage and early death.

The transplant technique is unique, because it allows a donors cells to gradually take over a patients bone marrow without using toxic agents to eliminate a patients cells prior to the transplant.

This case report is published in a letter to the editor in the journal Bone Marrow Transplantation.

For many adult patients with a blood disorder, treatment options have been limited because they are often not sick enough to qualify for a risky procedure, or they are too sick to tolerate the toxic drugs used alongside a standard transplant, said Rondelli, who is also division chief of hematology and oncology and director of the stem cell transplant program at UI Health.

This procedure gives some adults the option of a stem cell transplant which was not previously available.

Also, as biological research races forward, ethical quandaries are piling up. In a report published Tuesday in the journal eLife, researchers at Harvard Medical School, United States, said it was time to ponder a startling new prospect: synthetic embryos.

In recent years, scientists have moved beyond in vitro fertilization. They are starting to assemble stem cells that can organize themselves into embryolike structures.

Soon, experts predict, they will learn how to engineer these cells into new kinds of tissues and organs.

7 hours ago Natural Health

8 hours ago Policy & Politics

8 hours ago Features

The rest is here:
First patient cured of rare blood disorder with stem cell transplant - Guardian

Read More...

Peptide targeting senescent cells restores stamina, fur, and kidney function in old mice – Science Daily

Sunday, March 26th, 2017

Science Daily
Peptide targeting senescent cells restores stamina, fur, and kidney function in old mice
Science Daily
"Only in senescent cells does this peptide cause cell death," says senior author Peter de Keizer, a researcher of aging at Erasmus University Medical Center in the Netherlands. "We treated mice for over 10 months, giving them infusions of the peptide ...
Anti-aging peptide recovers fur growth, kidney health in miceMedical News Today
Aging signs reversed in mice by killing senescent cellsThe San Diego Union-Tribune

all 108 news articles »

Read more:
Peptide targeting senescent cells restores stamina, fur, and kidney function in old mice - Science Daily

Read More...

Metabolism and epigenetics play role in cancer development – Science Daily

Sunday, March 26th, 2017
Metabolism and epigenetics play role in cancer development
Science Daily
For the cells this means either unlimited growth, cancer, or death. Researchers ... Although cancer and stem cells can be challenged by chemical inhibition, mechanistic details of how chromatin and metabolites interact are yet to be defined. With both ...

and more »

Read the original post:
Metabolism and epigenetics play role in cancer development - Science Daily

Read More...

A Friend Dies As Scientists Ponder: Just How Preventable Are Most Cancers? – WBUR

Sunday, March 26th, 2017

wbur In this 2016 photo, a Chinese doctor Peng Limei looks at a CT scan of a lung cancer patient. (Andy Wong/AP)

This story is part of our "This Moment In Cancer" series. Sign up here to get series updates in your inbox.

A dear friend died of lung cancer this week.

She didnt smoke and she had no other risk factors. A retired nurse and avid cook, she ate an exemplary diet, maintained a lithe figure, and got an impressive amount of exercise climbing mountains and clearing trails.

Her death has left her many friends wondering why her? Her example undercuts the notion that any of us can ultimately do much to avoid an ugly death from cancer.

Dr. Bert Vogelstein of Johns Hopkins Medical Institutions says my late friend exemplifies the 50 percent or so of cancers he calls unpreventable.

"People want a reason why these cancers happen," Vogelstein says. "Well, heres the reason: Cells make mistakes. Thats just bad luck."

Those mistakes are like typos in a giant manuscript. Each time a cell divides, it mis-copies several molecules in the long chain of DNA that makes up our genes. Most of the time these biochemical mistakes are harmless. But sometimes they occur in genes that keep cancer in check. Once some of these mutations accumulate, the cell breaks free of normal constraints on its growth --that is, it becomes malignant.

"People want a reason why these cancers happen. Well, heres the reason: Cells make mistakes. Thats just bad luck."

Two-thirds of the mutations that give rise to cancer are these random copying errors, according to Vogelstein, biostatistician Cristian Tomasetti and their colleagues at Johns Hopkins University. Another 29 percent of cancer-causing DNA damage, they say, comes from environmental and behavioral factors such as cigarette smoking and obesity. The remaining 5percent are hereditary defects.

Vogelstein is a leading light in cancer research. He pioneered the concept that there are genes that suppress cancer and identified mutations in those genes that underlie many cancers.

The Hopkins researchers have been saying for two years that most cancer-causing mutations are these inescapable random errors at the heart of our most fundamental cellular workings. But their 2015 paper was heavily criticized, partly because it considered only U.S. cancer cases --other nations may have different or more environmental triggers. Also, the earlier report left out breast and prostate cancers, two of the most common types, so critics said it wasnt valid to generalize the findings to all cancers.

Their new paper, just published in Science, includes breast and prostate cancer in the 17 cancer types they analyzed. And it incorporates evidence on cancer incidence from 69 countries that account for two-thirds of the worlds population.

"This is the very first time that someone has ever looked at the proportion of mutations within each cancer type and assigned them to these three factors," Tomasetti said during a press briefing, referring to environment, heredity and random copying errors. "I consider this a completely new result compared to our previous one and a really fundamental one."

Their argument relies on a mathematical model that estimates the number of stem cells in each tissue type (the cells that must replicate to renew the tissue) and the number of times these cells divide over a lifetime. The rate of random mutations is fairly constant in different organs, they say, but different tissues turn over at different rates.

For instance, cells that make up the lining of the large intestine renew themselves every four days. That gives them more opportunity to accumulate mutations in the genes that drive cancer than cells in, say, the bone or brain. So it makes sense that colorectal cancer is the fourth most common major cancer, after lung, breast and prostate cancers.

What it doesn't mean

The finding that two-thirds of cancer-causing mutations are due to random mistakes does not mean that two-thirds of all cancers are due to bad luck. Thats because many cancers arise from a mix of factors.

Since it takes several mutational hits to kick-start a cancer, one or more of these might arise from internal random copying errors while others might come from external environmental sources, such as tobacco smoke. An individual born with a mutation that predisposes her to cancer might not get the disease unless or until random mutations in cancer-driving genes accumulate.

Breast cancer is an example of mixed causes. Most of the underlying mutations are due to random mutations, Vogelstein says. Some are due to an environmental factor such as obesity, age of first menstruation or whether a woman breast-fed. And about 10 percent stem from a strong hereditary predisposition, such as a BRCA gene.

Vogelstein says my late friend appears to represent a "pure" case of random bad luck, since smoking and behavioral risk factors were apparently not in play and lung cancer is not known to have a significant hereditary component.

The Hopkins teams findings, they say, are consistent with prior estimates that about 40 percent of all cancers are preventable, 5to 10 percent are due to inherited cancer genes, and around half are not preventable --since theres no way to avoid random DNA copying errors.

But what about environment?

But the work has been controversial up to now, and may remain contentious. It disturbs those who believe that changes in environment and behavior deserve top priority in the war against cancer.

Concluding that bad luck is the major cause of cancer would be misleading and may detract from efforts to identify the causes of the disease and effectively prevent it, Dr. Christopher Wild, director of the World Health Organizations International Agency for Cancer Research, complained after the first Vogelstein-Tomasetti paper came out.

Anne McTiernan of the Fred Hutchinson Cancer Research Center in Seattle remains unconvinced. "They say randomness is a major cause of cancer, and they said it last time," she told The Washington Post. "But the data doesnt convince me."

One group from Stony Brook University in New York did an analysis of the 2015 paper and concluded that extrinsic factors, such as environmental toxins, account for 70 to 90 percent of cancers while intrinsic ones the random copying errors when cells divide are to blame for only 10 to 30 percent.

The leader of the Stony Brook team says hes not convinced by the new report.

Vogelstein is philosophical about his critics. Its never easy to overturn dogma, he said in an interview. Like every new concept or idea that goes dramatically against the current paradigm, it will take awhile. It will take other people doing measurements we havent performed yet or even thought of. And hopefully people will accept it.

Less self-blame?

The implications for the way we think about cancer, and the strategies to fight it, are profound.

Most immediately, it might lessen the self-blame many cancer victims and their families feel --the sense theres something they did, or didnt do, that led to their diagnosis.

We hope this research offers comfort to the literally millions of patients who have developed cancer but who have led near-perfect lifestyles --who havent smoked, who have avoided the sun without sunscreen, who eat perfectly healthy diets, who exercise regularly, whove done everything that we know can be done to prevent cancer but they still get it, Vogelstein says.

Self-blame is particularly poignant for parents of children who get cancer. The Hopkins group believes that childhood cancers are entirely due to random mutations --except for the small percentage related to inherited gene defects.

When such parents read online that cancer is caused by environment or heredity, they often conclude theyre somehow to blame. "That causes a tremendous amount of guilt," says Vogelstein, a practicing pediatrician in his early career.

But the larger implication concerns the best strategy for fighting cancer.

Not preventing but nipping in the bud

Its not that classic prevention efforts, especially smoking cessation and healthier diets, dont deserve our continuing attention. But if around half of all cancers are due to random mutations --the price of biological mechanisms necessary for life --then theres no way to prevent those. That means we need to rely on early detection and treatment to maximize cures and minimize deaths.

We believe the first step in developing these strategies is simply recognizing these enemies exist, there are a lot of them, and theyre already here, inside us, Vogelstein says.

Right now, he says, funding for early detection and treatment is minuscule compared to that devoted to curing advanced, late-stage cancers.

One of the hottest areas of cancer research focuses on spotting the earliest signs of cancer, using such things as liquid biopsies to screen bodily fluids for evidence of cancer-causing mutations or telltale proteins produced by errant genes.

Vogelstein is prominent in this effort and has a personal stake such research. Hes the co-founder of two companies, PapGene and Personal Genome Diagnostics, that are trying to develop such high-tech diagnostics.

But early detection and treatment of cancer is fraught with pitfalls, as controversies over the risk-benefit ratio of mammography to detect early breast cancer and PSA testing for prostate cancer amply show. In large part thats because such tests often find cancers that dont need to be treated --that is, theyd never cause trouble if they werent treated. Doctors call this over-diagnosis.

There is certainly a problem with potential over-diagnosis, Vogelstein acknowledges. But that doesnt mean we should abandon the effort, especially now that were cognizant that many cancers arent preventable.

If Vogelstein and Tomasetti are right, they say, theres really no choice but to focus much more effort on nipping cancers in the bud. That's a long-term project.

Right now, for instance, many cancers are out of the gate and down the road before they're discovered. My friend's lung cancer, like so many with this fearful diagnosis, was too far advanced by the time it was found to even be slowed down by the most aggressive treatment.

So after living the healthiest life you can imagine, she spent her last days coping valiantly with the debilitating effects of the best cancer therapy her doctors could offer. It wasn't enough.

Richard Knox Senior Correspondent, CommonHealth Richard Knox is a senior correspondent for WBUR's CommonHealth.

More

Excerpt from:
A Friend Dies As Scientists Ponder: Just How Preventable Are Most Cancers? - WBUR

Read More...

Anti-aging peptide recovers fur growth, kidney health in mice – Medical News Today

Friday, March 24th, 2017

An anti-aging therapy could be one step closer; in a new study, researchers reveal how a peptide led to the destruction of cells that play a role in aging, reversing fur loss, kidney damage, and frailty in mice.

The research describes how the peptide stops levels of a protein called FOXO4 from increasing in senescent cells, which are cells that lose the ability to replicate and destroy themselves, but which remain metabolically active.

Senescent cells accumulate with age, and studies have shown that they can contribute to the aging process by causing damage to neighboring cells and impairing tissue function.

Previous research has shown that in senescent cells, levels of FOXO4 rise to prevent another protein called p53 from prompting the cells' self-destruction.

By blocking FOXO4 with the peptide, the research team has been able to restore programmed cell death, or apoptosis, in senescent cells.

"Only in senescent cells does this peptide cause cell death," says senior author Peter de Keizer, a researcher of aging at Erasmus University Medical Center in the Netherlands.

"FOXO4 is barely expressed in non-senescent cells, so that makes the peptide interesting, as the FOXO4-p53 interaction is especially relevant to those cells, but not normal cells."

On administering the peptide to fast-aging mice in regular doses, the researchers were able to reverse age-related conditions, such as fur loss and poor kidney health.

The findings were recently published in the journal Cell.

For their study, the researchers tested the peptide on older mice that had aged naturally and mice that had been genetically modified to age rapidly.

Both groups of mice developed characteristics and health problems commonly associated with aging, such as loss of fur, a decline in kidney health, and frailty.

Some of the rodents in each group were given infusions of the peptide three times a week for 10 months, while the remaining mice were monitored as controls.

Both the fast-aging and naturally aged mice saw improvements with peptide treatment, with no apparent side effects.

Within 10 days, the fast-aging mice began to experience fur regrowth. After 3 weeks, the naturally aged mice began to see improvements in fitness, compared with mice that did not receive the peptide.

Additionally, both the fast-aging and naturally aged mice started to demonstrate improvements in kidney function from 1 month after peptide treatment.

The team notes that the effects of peptide treatment were was so strong in fast-aging mice that doses needed to be reduced over the study period.

The researchers say that their findings support previous research showing that targeting senescent cells can help to reverse aging and increase lifespan, though much more research is warranted.

"The common thread I see for the future of anti-aging research is that there are three fronts in which we can improve: the prevention of cellular damage and senescence, safe therapeutic removal of senescent cells, to stimulate stem cells - no matter the strategy - to improve tissue regeneration once senescence is removed," says de Keizer.

He and his colleagues now plan to conduct a clinical trial to assess the safety of the peptide in humans.

Learn how exercise prevents cellular aging by increasing mitochondrial capacity.

More:
Anti-aging peptide recovers fur growth, kidney health in mice - Medical News Today

Read More...

‘Bad luck’ mutations increase cancer risk more than behavior, study says – fox5sandiego.com

Friday, March 24th, 2017

The uncrontolled division of cancer cells leads to the carcinogenesis.

The uncrontolled division of cancer cells leads to the carcinogenesis.

For the first time, researchers have estimated what percentage of cancer mutations are due to environmental and lifestyle factors, hereditary factors and random chance. Overall, 66% of the genetic mutations that develop into cancer are caused by simple random errors occurring when cells replace themselves, according to a new study published in the journal Science.

Environmental factors contribute 29% of mutations, while the remaining 5% are inherited, say Cristian Tomasetti and Dr. Bert Vogelstein, both of Johns Hopkins University.

In a previous paper, Tomasetti and Vogelstein asserted that your risk of developing cancer is largely based on random DNA errors that occur when self-renewing cells divide. In their new paper, they offer more detail describing how dumb luck plays a more significant role than either environmental, lifestyle or hereditary factors in causing this disease.

Every time a perfectly normal cell divides, as you all know, it makes several mistakes mutations, explained Vogelstein in a briefing. Now most of the time, these mutations dont do any harm. They occur in junk DNA, genes unrelated to cancer, unimportant places with respect to cancer. Thats the usual situation and thats good luck.

Occasionally, one of these random miscopies will occur in a cancer driving gene.

Thats bad luck, said Vogelstein.

Though this fact may be demoralizing to some people, researchers noted it might bring comfort to people with cancers they worked to prevent or the parents of children with cancer.

Your lifestyle still matters

In a previous research paper published in 2015, Tomasetti and Vogelstein used a mathematical model to first present this idea that cancer risk is strongly correlated with the total number of divisions undergone by normal cells. For 31 cancers, the researchers first estimated the number of stem cells in tissues where disease arose and then they estimated the rate at which these cells divide. Comparing these to incidence of these cancers in the United States, the two researchers found a strong correlation between cell division and lifetime risk of each given cancer.

For their new study, Tomasetti and Vogelstein worked with Lu Li, a doctoral student at Johns Hopkins Bloomberg School of Public Health, to analyze genome sequencing and epidemiologic data from 32 cancer types, including breast and prostate cancers. This time, the research team concluded that nearly two-thirds of mutations in these cancers are attributable to random errors that occur naturally in healthy, dividing cells during DNA replication.

Drilling deeper, they searched 423 international cancer databases to examine data from 69 countries spanning 6 continents, representing 4.8 billion people or two-thirds of the worlds population. Then, as theyd done in their previous study, they estimated stem cell divisions in different human tissues and compared this to lifetime incidence of 17 cancer types.

Once again, their new mathematical model showed a high correlation between cancer incidence and the total number of divisions of normal cells. This time, though, their finding that 66% of all genetic mutations leading to cancer are caused by random errors crossed borders and so ranged across many different potential environmental factors that might lead to cancer.

While this randomness is upsetting, even mutations caused by environmental or lifestyle factors are haphazard, explained Tomasetti.

Take smoking: Cigarette smoking undoubtedly leads to more genetic mutations than might normally happen, yet where the DNA defects occur on a smokers genome is completely accidental. In other words, mutations caused by smoking, just like random mutations, can affect either cancer driving genes or stretches of DNA that are irrelevant to cancer.

Lifestyle factors still matter for cancer prevention.

Just one mutation is not sufficient to cause cancer typically three or more mutations must occur, Tomasetti noted. If, say, your cells miscopy DNA and so cause two random mutations, a third mutation is still needed. Obesity, smoking, lack of exercise and poor eating habits might supply that necessary third gene defect that tips your body into a disease state.

The new study, then, does not let us off the hook: We play a role in protecting our good health.

Paradigm shift

Since the 1970s, the accepted wisdom underlying cancer research was that genomic alterations caused cancer and most of these alterations are mutations, explained Tomasetti. As envisioned by scientists, DNA defects cause the haywire growth of cells which disturb the natural processes of your body.

Naturally, that leaves one fundamental question: What causes these mutations?

Widespread belief suggests the majority of cancers are caused by behavioral and environmental factors, with inherited genetic mutations causing the remainder of cases.

This is the current paradigm and we feel that our new research breaks this paradigm, said Tomasetti. We discovered theres a third factor that actually causes most of the mutations random errors made during normal cell division.

So why was this never appreciated before? It was never measured before and when you measure something you can have a sense of how important that is, said Tomasetti.

In an editorial published alongside the new study, Martin A. Nowak, a professor of mathematics and biology at Harvard University, and Bartlomiej Waclaw, a researcher at University of Edinburgh, wrote that a large portion of the variation in cancer risk among tissues can be explained, in the statistical sense, by the number of stem cell divisions.

An understanding of cancer risk that did not take bad luck into account would be as inappropriate as one that did not take environmental or hereditary factors into account, Nowak and Waclaw wrote.

While Tomasetti and Vogelsteins first paper led to no less than a few hundred papers written in response, their new study appears to be more soothing to the nerves.

Answers for those who did everything right

I was concerned about the last article, because it didnt talk enough about prevention and it left people thinking, Gee youre just destined to get cancer and you cant do anything about it,' said Dr. Otis Brawley, chief medical officer of the American Cancer Society. Brawley, who was not involved in the research said he was much happier with the current paper, even if it doesnt tell me anything I hadnt known for the last 20 years.

Bert Vogelstein is an incredibly well-respected, well-known cancer biologist who published a paper very similar to this you might even call it part one of this paper two years ago, said Brawley, explaining the original paper caused quite a stir because it implied that almost all cancers were not preventable.

And it really upset the anti-smoking people, it upset the folks who are in the nutrition and physical activity for cancer prevention he really upset the prevention crowd, said Brawley, who believes the new paper is generally a better explanation of the original theory.

Keep in mind its a mathematical simulation, its not a clinical trial, but [Vogelstein is] noting that a certain number of cases are due to replication error, DNA replication error, in normal growth, said Brawley. Those are cancers we really cannot do a lot to prevent.

Brawley described counseling a 47-year old woman who said shed done everything right: She ate healthy, exercised, didnt smoke and got yearly mammograms. Despite having a clean mammogram just six months earlier, she was diagnosed with stage 4 breast cancer.

How did this happen to me? she asked Brawley.

The answer is she had a replication error, said Brawley. And the way you think about replication error is DNA is always being copied throughout your body a million times every day, you know, cells die off and cells are replaced. We have mitosis and an important thing in cell duplication or mitosis is DNA is replicated or copied and the DNA is supposed to be copied exactly and occasionally theres a misreplication or miscopying.

Brawley appreciates the fact that Tomasetti and Vogelstein acknowledge the past controversy and make a point in their new paper of addressing prevention and detection.

I think that we need to have a balance between cancer prevention efforts as well as what I would call wise early detection or wise screening efforts, said Brawley.

Theres a tendency in the US to think that every screening test is great. Unfortunately there are screening tests that actually cause more harm than good, said Brawley.

In the 1960s and 1970s, we stopped doing chest X-ray screening for lung cancer because, after 20 years of doing it, we finally got around to doing an assessment and we found the death rates were higher in the screened versus the unscreened group, said Brawley. The reason? When a patients chest X-ray was found to be abnormal, the follow-up biopsy might cause a collapsed lung or heart attack, he explained.

We still have huge debates whether theres a benefit to prostate cancer screening. There, the benefit might be to a subset of men and not to all men thats an unknown, thats a question mark, said Brawley.

When it comes to mammography screening, thats something all of us believes saves lives but its not perfect, said Brawley.

The best studies that we have show that mammography reduces risk of death by 30%, said Brawley. That means if you have a group of women who habitually get screened, get good high quality screening, mammography is not going to help 70%.

According to Vogelstein, the new study is important for two reasons.

We hope this research offers comfort to the literally millions of patients who have developed cancer but have led near perfect lifestyles, said Vogelstein. Non-smokers who have avoided the sun, these cancer patients eat healthy diets, exercised and done everything to prevent cancer. But they still get it, said Vogelstein.

Its important, especially for parents of children who have cancer, that people understand the root causes of cancer.

The first thing someone looking on the web would see is cancer is caused by environment or heredity, said Vogelstein. When it comes to the parent of a child with cancer, they think they either transmitted a bad gene or exposed their child to an environmental agent that caused disease.

This causes a tremendous amount of guilt, said Vogelstein, who is also a pediatrician and has seen such cases. We dont need to add guilt to an already tragic situation.

The second reason the study is important is because cancer will strike about 1.6 million people in the United States this year. And it will kill 600,000 of us, said Vogelstein. We need a completely new strategy.

He hopes new awareness of these random mutations will inspire many scientists to devote their efforts to various strategies to limit the damage that these internal enemies do.

The first step is simply recognizing these enemies exist, said Vogelstein.

See original here:
'Bad luck' mutations increase cancer risk more than behavior, study says - fox5sandiego.com

Read More...

Macchiarini’s seventh transplant patient dies – The Local Sweden

Wednesday, March 22nd, 2017

Italian surgeon Paolo Macchiarini. Photo: AP Photo/Lorenzo Galassi

A seventh patient of Italian surgeon Paolo Macchiarini, who was fired from a Swedish university over accusations of misconduct, has died.

Macchiarini performed two synthetic trachea transplants on Yesim Cetir, 26, in Stockholm in 2012 and 2013, but she suffered brutal complications until her death.

In the early hours of Monday, her father Hayrullah Cetir announced on his Facebook account that Yesim died at Temple University Hospital in Philadelphia.

"My daughter Yesim died tonight [Sunday] at 9.15pm may she rest in peace," he wrote, publishing a picture of her in a hospital bed.

Macchiarini operated on eight patients between 2011 and 2014, three of them at the prestigious Stockholm-based Karolinska Institute, which selects the winners of the Nobel Prize in medicine.

Only one of the patients survived after having a synthetic trachea, designed and implanted by Macchiarini, removed during a surgery in Russia in 2014.

Cetir was the victim of two failed surgeries as her trachea was first badly damaged during treatment in Turkey before she received surgery in Stockholm.

She went to the United States to receive a trachea from a donor, without being able to recover.

"It is with great sorrow that I offer my sincere condolences to Yesim Cetir's family after having heard about her death. It would of course be inappropriate to discuss her earlier medical condition and treatment," Macchiarini said in a written comment to Swedish public broadcaster SVT.

The surgeon gained worldwide fame in 2011 by carrying out the world's first graft of an artificial plastic trachea, which was to be colonized by the patients' stem cells.

While he said in the medical journal The Lancet that the technique was working, successive deaths of his patients and falsifications in the article led him to be sacked.

Macchiarini was suspected of having embellished his resume to be hired by the Karolinska Institute. He is being investigated by Swedish police.

The scandal hit the Nobel Prize and caused several resignations within the institute.

Read the original post:
Macchiarini's seventh transplant patient dies - The Local Sweden

Read More...

Science to Beat the Death: 200 300 years old human in the Future! – Sri Lanka Guardian

Wednesday, March 22nd, 2017

Interview by Kev Kharas Photography byDamien Maloney Courtesy: Unlimited.World

(March 22, 2017, Boston, Sri Lanka Guardian) Russian-born Maria Konovalenko is one of the most visible faces at work in the pro-longevity community today. A zealous advocate for the fight against human ageing and a PhD scientist and researcher at the trailblazing Buck Institute in California, her ultimate goal is to use advances in science and technology to help people live the longest, healthiest lives they possibly can.

Her ethos that ageing and dying should be seen as diseases that humanity can work together to cure challenges everything we understand about natural life cycles. It also hints at the possibilities that lie ahead for radical human lifespan extension an extra 30 years in her lifetime, she conservatively estimates, then rapidly up to 200, 300. Beyond that, lies the rather more distant goal of human immortality.

VICE: Can you give me a broad overview what youre up to currently?

Maria K:Im in the third year of my PhD inBiology of Aging, set up by USC and the Buck Institute, the leading organisations in the field. I became a student here in the programmes first year so basically it started with us, were the guinea pigs. I feel incredibly privileged. Im focusing on ageing and stem cells in mouse tracheas were trying to figure out which genes are responsible for the failure of tissue to replenish itself.

With the emergence of things like the Google-fundedCalico Labs, would you say theres been a more concerted push to understand the secrets of immortality in recent years?

Not immortality. Were way off that. What were looking at now are the basic mechanisms that drive ageing, figuring out why our bodies lose their regenerative potential over time. Some people are answering different questions for example, why do we develop neurodegenerative pathologies, like Alzheimers? Were all looking at different mechanisms and then trying to interfere with them to slow down ageing. You can extend the lifespan of a worm ten times thats unbelievable! but when you look at more complex animals, like mammals, its not as effective.

What do you think we can expect within the limits of our lifetime?

If youre in your sixties or seventies, hopefully, within the next decade or so, well have a therapy that will extend your health span the years in which youre generally healthy and free from disease. Thats based on recent discussions at one of the big ageing conferences, and what some of the key biologists believe. If youre in your thirties, your life expectancy and the probability of more breakthrough techs being developed is way higher.

We could develop a combination of things that have a synergistic effect. For example: the Buck Institutes Dr Pankaj Kapahi created a worm that had two tailored genetic mutations if administered separately, these mutations had been shown to give about 100 and 60 percent extra lifespan, respectively. But, administered together, they didnt yield to a 160 percent increase in lifespan it was actually an increase of almost 500 percent!

How could AI help expand human lifespan?

AI could change the fate of humanity. People in biology are already dealing with tons of data, but AI would be able to come up with models and predictions based on the entire breadth of existing human knowledge in biology, very quickly. Heres an example: the IBM AI-supercomputer Watson was able to digest all our collective cancer knowledge and diagnose cancer patients more accurately than human physicians. AI wouldnt just be the tool that scientists use it would be the scientist.

What kind of opportunities could radically extended lifespans give us as a species?

I think that liberation from biological ageing is one of the most wonderful things that could happen to humans. We could end pain, disease, suffering; we could go to different planets, deal with the technological problems that space travel poses, create new worlds.

What do you think the global economy might look like in such a world?

Everything would immediately be different in a world with AI. Its very hard to make any meaningful predictions beyond its arrival. But I believe that when it does, technological progress will be the main driver of the economy. The economy of the previous two centuries was driven by what was inside the Earth oil, gas, things like that. Right now, the most expensive companies are tech companies.

If people were born into a world with the expectation of significantly longer life 200, 300 years what do you think would happen to punishments for crimes likemurder?

It would be costly for the government to keep criminals alive in prison for 200, 300 years. Wed have to rethink our old penitentiary system. If a person has done something wrong, maybe we could use tech to change underlying psychological factors that caused the person to commit the crime in the first place. Maybe well come up with a neurotransmitter cocktail, for example, that lets us treat criminals as if violence is a curable disease?

How about the ideal of romantic monogamy if people are living much longer, will they still want to spend their entire lives with one person?

People are very interesting creatures because our relationships adapt and change along with us. I know I might sound extremely optimistic, but there are way too many dystopias in the movies; how might the world look if everything goes right? If the future-society changes so much that monogamys no longer beneficial for an individual, then people will adapt. Chances are the number of pairs staying together for life will decrease. But I dont think it will hit zero.

As a generation, what kind of legacy do you think we should be looking to leave behind?

Definitely extending lifespan and health-span by somewhere in the region of 30 percent. This will happen within the coming few decades. As for the bigger legacy, people are building the base of the algorithms that will hopefully create AI in the more distant future. So that will probably be part of our legacy, too.

Do you believe in life after death?

I dont. However, have you seenBlack Mirror? The San Junipero episode I believe thats a very basic, optimistic representation of what mind uploading might look like in the future. If you could somehow transfer consciousness from a biological subject into some kind of storage device that could be life after death.

Is that something youd enjoy?

Absolutely. I dont want to die. You would be forever young.

Why would you like to live forever?

I would like to implement my dreams. And they range from having a pair of wings, to being able to drink a cocktail in a bar on Mars, to solving the existing problems of the world economic inequality, diseases that make our lives miserable, things like that. I have an endless list of dreams. And thats why I need an endless amount of hours.

Featured image: Maria at the Buck Institute for Research on Aging in Novato, California, credit Damien Maloney

Link:
Science to Beat the Death: 200 300 years old human in the Future! - Sri Lanka Guardian

Read More...

Blinded by science: Women go blind after stem-cell treatment at Florida clinic – MyPalmBeachPost (blog)

Wednesday, March 22nd, 2017

Three women reportedly went blind after a stem cell treatment at a Florida clinic.

Whats more is that at least two of the women had gone to the clinic because it was listed as a macular degeneration study on a federal database.

Doctors call the incident an example of how risky such clinics can be.

News reports from The Associated Press, The New England Journal of Medicine and others say that a clinic the experimental procedure occurred was in Sunrise, Florida run by U.S. Stem Cell Inc.

Age-related macular degeneration can rob a person of their central vision.

The women were injected in their eyes with a cell preparation derived from her own fat tissue.

Ophthalmologist Dr. Thomas Albini of the University of Miami, who examined the women, said one woman is totally blind and the others legally blind. He said all suffered detached retinas.

These women had fairly functional vision prior to the procedure and were blinded by the next day, Albini said.

The clinics method hasnt been proven effective or tested for safety in people, he added.

Its very alarming to us as clinicians that somebody would do this to both eyes at the same time, said Albini.

Dr. Thomas Albini of the University of Miami.

Elizabeth Noble, one of the women said she was diagnosed with age-related macular degeneration that blurs the central vision. The former educator said she heard about the treatment at the clinic for a research study described on ClinicalTrials.gov, a website run by the National Institutes of Health.

The former educator said she heard about the treatment at the clinic for a research study described on ClinicalTrials.gov, a website run by the National Institutes of Health.

Its very easy to register studies on ClinicalTrials.gov and essentially use a government website as a marketing device, Leigh Turner, a bioethicist at the University of Minnesota, told BuzzFeed News.

Noble went to the clinic in June 2015 where staff took fat from around her belly button, extracted those cells and mixed them with Nobles blood plasma. They then injected it into both her eyes for $5,000, according to a story in Buzzfeed.

In an editorial accompanying the Journals report, stem cell expert Dr. George Daley, dean of Harvard Medical School, called the clinics treatment careless.

This report joins a small but growing medical literature highlighting the risks of such wanton misapplication of cellular therapy, he wrote. Providing such treatments for profit outside a proper research setting is a gross violation of professional and possibly legal standards, he said.

Buzzfeed reports this isnt the first time experimental procedures at a clinic have gone awry.

In 2010, for example, a woman with the autoimmune disease lupus died after her own bone marrow cells were injected into her kidneys at a clinic in Thailand.

In 2013, the Florida Department of Health revoked the medical license of Zannos Grekos over the death of a 69-year-old woman. He had extracted material from her bone marrow, filtered it, and then infused it into the arteries feeding her brain. The woman had a stroke.

Treatment for age-related macular generation is at the center of the Medicare fraud trial in West Palm Beach of Dr. Salomon Melgen, who happens also to be tied to a bribery scandal involving a U.S. senator.

Read The Palm Beach Posts coverage of the fascinating Melgen trial by clicking here.

Like Loading...

See the article here:
Blinded by science: Women go blind after stem-cell treatment at Florida clinic - MyPalmBeachPost (blog)

Read More...

First patient cured of rare blood disorder – Science Daily

Tuesday, March 21st, 2017

Science Daily
First patient cured of rare blood disorder
Science Daily
CDA is a rare blood disorder in which the body does not produce enough red blood cells, causing progressive organ damage and early death. ... "This procedure gives some adults the option of a stem cell transplant which was not previously available.".

and more »

Read this article:
First patient cured of rare blood disorder - Science Daily

Read More...

Blinded by science: Women go blind after stem-cell treatment at Florida clinic – Palm Beach Post (blog)

Tuesday, March 21st, 2017

Palm Beach Post (blog)
Blinded by science: Women go blind after stem-cell treatment at Florida clinic
Palm Beach Post (blog)
In 2010, for example, a woman with the autoimmune disease lupus died after her own bone marrow cells were injected into her kidneys at a clinic in Thailand. In 2013, the Florida Department of Health revoked the medical license of Zannos Grekos over the ...
Stem cell therapy is safe for stroke patients, study showsScience Daily

all 32 news articles »

More here:
Blinded by science: Women go blind after stem-cell treatment at Florida clinic - Palm Beach Post (blog)

Read More...

Page 26«..1020..25262728..40..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick